Rationalising the role of Keratin 9 as a biomarker for Alzheimer’s disease by Richens, Joanna L. et al.
Un
co
rre
cte
d p
roo
f
1Scientific RepoRts | 6:22962 | DOI: 10.1038/srep22962
www.nature.com/scientificreports
Rationalising the role of Keratin 
9 as a biomarker for Alzheimer’s 
disease
Joanna L. Richens1, Hannah L. Spencer1, Molly Butler1, Fiona Cantlay1, Kelly-Ann Vere1, 
Nin Bajaj2, Kevin Morgan3 & Paul O’Shea1
Keratin 9 was recently identified as an important component of a biomarker panel which demonstrated 
a high diagnostic accuracy (87%) for Alzheimer’s disease (AD). Understanding how a protein which is 
predominantly expressed in palmoplantar epidermis is implicated in AD may shed new light on the 
mechanisms underlying the disease. Here we use immunoassays to examine blood plasma expression 
patterns of Keratin 9 and its relationship to other AD-associated proteins. We correlate this with the 
use of an in silico analysis tool VisANT to elucidate possible pathways through which the involvement 
of Keratin 9 may take place. We identify possible links with Dickkopf-1, a negative regulator of the wnt 
pathway, and propose that the abnormal expression of Keratin 9 in AD blood and cerebrospinal fluid 
may be a result of blood brain barrier dysregulation and disruption of the ubiquitin proteasome system. 
Our findings suggest that dysregulated Keratin 9 expression is a consequence of AD pathology but, as it 
interacts with a broad range of proteins, it may have other, as yet uncharacterized, downstream effects 
which could contribute to AD onset and progression.
Keratin 9 is a 623 amino acid type 1 cytokeratin expressed predominantly in the skin1. Mutations within the 
KRT9 gene (Keratin 9) have been strongly associated with the skin disorder Epidermolytic palmoplantar kerato-
derma2–4. More recently however, evidence has emerged demonstrating alternative expression sites of Keratin 9 
including natural killer cell membranes5, intestinal extracellular exosomes6, sperm nuclei7, tears8, follicular fluid9 
and blood serum10 with several of these studies implicating the molecule in disease pathology. Dysregulated 
expression of Keratin 9 has, for example, been implicated in polycystic ovary syndrome9 and suggested as a met-
astatic marker of hepatocellular carcinoma10.
Of particular interest is recent evidence suggesting that Keratin 9 may be implicated in neurological disorders 
including dementia. Cerebrospinal fluid (CSF), a fluid produced by brain ventricles and which surrounds the 
central nervous systems, has been a target for studies into neurological disorders as it is contiguous with brain 
interstitial fluid and is, therefore, indicative of brain pathology11. A review of the CSF proteome found evidence 
of Keratin 9 expression in CSF using both ESI Ion Trap/FT-ICR (18 peptide sequences) and MALDI TOF/TOF 
(23 peptide sequences)12 mass spectrometry. These findings were further substantiated by a 2012 study in which 
2D electrophoresis examination of CSF demonstrated that levels of Keratin 9 expression in both Multiple Sclerosis 
and Neuromyelitis Optica patients were twice that of control individuals13.
Alzheimer’s disease (AD), the most common form of dementia14, is posing a huge societal problem and indi-
cators of disease that can be utilised in identification and monitoring of disease progression are vital14. A pro-
teomic study of CSF undertaken by Vafadar-Isfahani et al. identified Keratin 9 as an important component of a 
biomarker panel for diagnosing AD15. The power of these markers resided in their combined use as a complete 
biomarker panel, but the existence of any marker within the panel is suggestive of some involvement in the 
mechanisms underlying AD pathology. A subsequent study undertaken within our laboratory utilised immu-
noassays to examine Keratin 9 expression in ‘matched’ CSF and blood plasma samples collected simultaneously 
from individual donors16. This study provided further validation of the presence of Keratin 9 in both CSF and 
blood plasma. Interestingly, Keratin 9 was detected exclusively in CSF collected from patients with AD but not in 
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healthy individuals. Whilst the majority of the other components of the biomarker panel15 had previously been 
linked to AD17–21, it was thought that these studies were the first to implicate Keratin 9 (and also Tetranectin) in 
AD pathology. It has since emerged, however, that a previous study by Mueller and colleagues in 2010 used mass 
spectrometry to demonstrate dysregulation of Keratin 9 expression levels in AD22 substantiating our previous 
findings15,16. In addition to this, a recent study undertaken by Li et al. identified Keratin 9 amongst a number of 
potential molecules and pathways involved in AD pathology, although its involvement within these mechanisms 
was not expanded upon23.
Whilst the understandable focus of many biomarker studies, including those mentioned above, is to identify 
molecules with high diagnostic utility they do also offer the often overlooked opportunity to obtain a further 
understanding of the mechanistic origins of any disease. As evidence lends strength to the potential importance 
of Keratin 9 in AD, it also raises the question of how a protein typically associated with the skin can be intimately 
involved in a neurodegenerative disorder. The question of what has led to dysregulation of its normal expression 
pattern therefore requires attention and particularly whether it is a cause or consequence of the disease process.
In the present study we aim to shed light on the potential involvement of Keratin 9 in AD. Expression pat-
terns of Keratin 9 in blood plasma samples from AD and healthy patient cohorts are examined to determine its 
diagnostic utility as a stand-alone biomarker and its relationship with other AD-associated protein targets. This 
is followed by a detailed in silico investigation of potential mechanisms and pathways through which Keratin 9 
could influence disease pathology. These in silico studies were undertaken using the VisANT pathways analysis 
package developed at Boston University and based upon the Predictome database (http://visant.bu.edu)24. This 
software enables examination of the biological interactions of an experimentally determined biomarker, facilitat-
ing construction of molecular pathways and networks that are associated with the disease condition. In a previ-
ous study we applied VisANT analysis protocols to AD-related gene and protein panels in order to explore and 
redefine the mechanistic basis of the disease25. Other studies that utilised VisANT include investigations into the 
mammalian 14-3-3-phosphoproteome26, the involvement of the Stat5a network in prostate cancer27 and the role 
of FoxP1 in the regulation of autism-related pathways28. Identification of molecular pathways of which Keratin 9 
is a potential component allows discussion on how Keratin 9 expression could influence or be influenced by AD 
pathology. Understanding the mechanisms which are associated with these pathways therefore could lead to the 
identification of novel drug targets or additional diagnostic biomarkers.
Methods
Patient samples. This study was approved by the local Ethics Committee, NRES Committee East Midlands, 
Ref 12/EM/0052. All methods were carried out in accordance with the approved guidelines and all participants 
provided written informed consent. Case samples were diagnosed as either confirmed or probable AD according 
to the Consortium to Establish a Registry for Alzheimer’s disease (CERAD) guidelines. All patients were diag-
nosed as Late-Onset Alzheimer’s disease (LOAD). Patients with significant cognitive comorbidity, including but 
not limited to head trauma, alcoholism, learning disability or Parkinson’s disease, were excluded from the study. 
The demographics of the sample cohorts analysed within this study are identified in Table 1.
Protein detection by Immunoassay: ELISAs. Keratin 9 was detected according to the manufacturer’s 
protocol using an ELISA kit purchased from antibodies-online GmbH (ABIN417500). Plasma and CSF samples 
(diluted 1:1) were incubated in wells pre-coated with a capture antibody for 2 hr followed by incubation with a 
biotinylated detector antibody for 1 hr and a 30 min incubation with horseradish peroxidase-conjugated avidin. 
The reaction was developed using TMB substrate solution, stopped with 1 M HCl and read at 450 nm. All assay 
steps were undertaken at 37 °C. All samples and standard curves were measured in duplicate and concentrations 
of Keratin 9 in the clinical samples were determined from the standard curve generated using the standards pro-
vided in the kit.
Amyloid beta peptide 42 (Aβ 42) was detected using a commercially available ELISA kit processed accord-
ing to manufacturer’s instructions (Wako Chemicals GmbH; 296–64401). All samples and standard curves were 
measured in duplicate and concentrations of Aβ 42 in the clinical samples were determined from the standard 
curve generated using the reagents provided in the kit.
SPARC-like 1 (SPARCL1) was measured by ELISA as previously described16. Briefly, ELISA plates were coated 
overnight with 5 μg/ml capture antibody (CAB-701MH in PBS; Creative Biomart). Following this and all subse-
quent incubations wells were washed three times with PBS-0.05% Tween20 (PBST). A blocking solution of PBST-
1% BSA was applied to antibody-coated wells for 1 hr prior to addition of 50 μl sample (either clinical sample or 
protein standard) for 2 hr. Biotinylated detection antibody (BAF2728; R&D Systems) was added at 500 ng/ml for 
2 hr and the reaction was developed using streptavidin-HRP and TMB substrate, stopped with 1 M HCl. Samples 
were read at 450 nm with concentrations of SPARCL1 determined from a standard curve generated with recom-
binant SPARCL1 (R&D Systems; 2728-SL).
Healthy Cohort AD Cohort
Sample number 60 58
Gender (M/F) 25/35 31/27
Age at entry (years ± SD) 80.33 ± 6.64 79.03 ± 6.96
Time between study entry and 
recalled onset (years ± SD) — 4.32 ± 2.71
Table 1.  Patient demographics of the blood plasma samples used within this study.
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Protein detection by Immunoassay: Luminex assays. Apolipoprotein E (ApoE), Clusterin, 
Fibrinogen and Tau concentrations were determined using Luminex assays developed in-house as previously 
described16. Briefly, monoclonal capture antibodies to the target proteins were coupled to COOH-coated flu-
orescently dyed microspheres (Bio-Rad, Hercules, CA) using the Bio-Plex Amine Coupling Kit (Bio-Rad, 
171–406001) according to manufacturer’s instructions and as previously validated16. A bead suspension con-
taining 5000 of each antibody-conjugated bead set was added to designated wells of a filter plate (pre-wetted 
with wash buffer (PBST)), washed twice with PBST and resuspended in incubation buffer (PBS-1% BSA). To 
this, a sample of appropriately diluted clinical sample or protein standard mixture was added, and the plate was 
incubated for 2 hr at 25 °C on a rotating plate shaker (600 rpm). Wells were washed, incubated with a cocktail of 
biotinylated detector antibodies (containing each antibody at a pre-determined optimal concentration) for 1 hr, 
washed again and incubated for 30 mins with streptavidin-RPE. Wells were then washed to remove unbound 
streptavidin-RPE prior to analysis. Data was acquired on a Bio-Plex 200 system and analysed with associated 
software (Bio-Rad). All samples and standard curves were performed in duplicate and in each well, a minimum 
of 100 beads per target molecule were analysed for both bead designation and R-phycoerythrin fluorescence. 
Concentrations of the target proteins within the clinical samples were determined from standard curves gener-
ated using recombinant proteins.
In silico analysis. In silico protein association studies were undertaken using the free licence software 
VisANT (http://visant.bu.edu)24. This network analysis tool is constructed around the Predictome database29 
which contains details of experimentally-derived biological interactions collated from a variety of data sources24. 
An initial search of Keratin 9 interactions was undertaken to identify binding partners of the molecule. The poten-
tial contribution of Keratin 9 to AD pathology was then examined through investigation of the biological inter-
actions of Keratin 9 with the well-established AD-associated molecules ApoE, amyloid precursor protein (APP) 
and Tau30–32. Searches were undertaken using the primary UniProt accession number of the appropriate proteins; 
P35527 (Keratin 9), P05067 (APP), P02649 (ApoE) and P10636 (Tau). An interactome was defined as the network 
of interactions that occurs between the target molecules under consideration. Interactions were restricted to those 
which occur no more than one degree away from the inputted molecules. The components identified within the 
derived interactome were further analysed using the free, open access pathway database Reactome (www.reac-
tome.org)33 to identify potential pathways through which they may contribute to AD pathology.
Statistics. Data was analysed using GraphPad Prism Version 6.04. Cohorts were compared using the 
Mann-Whitney test and Spearman correlation coefficients were determined as appropriate. A p-value ≤ 0.05 
was considered to be a practical level of clinical significance. Significance values are denoted by asterisks as 
defined by GraphPad Prism version 6.04: ****extremely significant (p < 0.0001); ***extremely significant 
(0.001 ≤ p ≤ 0.0001); **very significant (0.01 ≤ p ≤ 0.001); *significant (0.05 ≤ p ≤ 0.01).
Results & Discussion
Keratin 9 Expression and Correlations with Other AD-associated Proteins. Keratin 9 expres-
sion levels were examined in blood plasma samples from a cohort comprising 60 healthy individuals and 58 
AD patients, as shown in Fig. 1A. The actual concentrations observed in this cohort were lower than those 
obtained for an alternative cohort in a previous study16, however, the trends observed were analogous, with 
expression levels decreasing in healthy individuals (Mean = 34.7 ± 47.6 pg/ml) when compared to AD patients 
(Mean = 64.4 ± 88.0 pg/ml). The variation in concentrations observed between the different studies may be due 
to the use of different anticoagulants during blood collection, a factor which is known to affect metabolite con-
centrations34. Whilst still not reaching significance, the p-value of the change due to AD decreased for the larger 
cohort (p = 0.1399; n = 58 AD/60 Healthy) indicating that it may continue to improve as the sample size increases. 
In Fig. 1B, there appears to be some level of association between blood plasma Keratin 9 concentration and age 
in healthy individuals, (r = − 0.2316; p = 0.075) which is dysregulated in the AD cohort (r = 0.1646; p = 0.2168).
In order to gain an understanding of the role of Keratin 9 in AD, interactions with other AD-associated pro-
teins were sought. Immunoassays of Aβ 42, ApoE, Clusterin, Fibrinogen, SPARCL1 and Tau15,16,35 were under-
taken on blood plasma samples from the two patient cohorts. The concentrations of these proteins are detailed in 
Figure 1. Keratin 9 expression in blood plasma in healthy and AD patient cohorts (A) and the correlation of 
these concentrations with the age of healthy (B(i)) and AD (B(ii)) individuals.
Un
co
rre
cte
d p
roo
f
www.nature.com/scientificreports/
4Scientific RepoRts | 6:22962 | DOI: 10.1038/srep22962
Table 2. It should be noted that, whilst not the focus of this study, a significant difference (p = 0.0063) between the 
concentration of fibrinogen in the healthy (49.59 ± 20.72 μg/ml) and AD (41.57 ± 21.72 μg/ml) patient samples 
was observed lending weight to previous studies which identify it as a potential biomarker of AD36. Additionally, 
the correlations between age and concentration of ApoE, SPARCL1 and Tau were found to be disrupted upon 
onset of AD whilst the correlation between Aβ 42 and age strengthened in the AD cohort when compared to 
healthy individuals (Table 2).
When the relationship between concentrations of Keratin 9 and Aβ 42, ApoE, Clusterin, Fibrinogen, SPARCL1 
and Tau were examined (Table 3), significant correlations were demonstrated between blood plasma concen-
trations of Keratin 9 and ApoE, Clusterin or Tau. The strength of all these correlations was found to increase 
in the AD cohort when compared to the healthy individuals. A correlation with SPARCL1 was observed, but 
the strength of this association remained unchanged between the two cohorts. No correlations were identified 
between blood plasma concentrations of Keratin 9 and Aβ 42 or Fibrinogen in either the healthy or AD cohorts 
(Table 3).
Before speculating on the meaning of these results, the possibility of contamination was also addressed. Due 
to the expression of Keratin 9 in the outer, terminally differentiated epidermis, it is present in shed skin, which 
is a major component of dust. However unlikely, it is conceivable, that results from some previous studies could 
have attributed dust contamination to the detection of Keratin 937. Furthermore, taking blood and CSF samples 
involves puncturing the skin, and as such may be a route through which keratinocyte components could enter 
the clinical samples. ELISA measurements of Keratin 9 in both AD patients and healthy controls collected within 
this study suggest that there is some level of expression in both cohorts (Fig. 1A). Whilst the possibility of con-
tamination causing these baselines levels of expression cannot be disregarded, it cannot account for studies where 
differences in expression levels have been identified in identically handled samples. Work in our laboratory has 
previously identified the presence of Keratin 9 in AD CSF but not in normal CSF16 substantiating the significance 
of our findings and suggesting that there is a biological basis behind the results as opposed to contamination.
Initial in silico Analysis. The data outlined above suggests that Keratin 9 may be implicated in the mecha-
nistic pathways underlying AD. To further ascertain the nature of association, in silico protein association studies 
were undertaken using VisANT software, as described in Methods. Initially, the known interacting partners of 
Keratin 9 were examined with the interactome produced by these molecules illustrated in Fig. 2. This identified 
54 proteins that have been experimentally proven to interact with Keratin 9, which are listed in Table 4, along with 
the experimental methods used to ascertain these interactions. Current knowledge of the function of Keratin 9 is 
limited; it has been shown to provide scaffolding to cells3 and act as an epidermal differentiation marker38. This 
Molecule
Healthy Cohort AD Cohort
Concentration
Correlation with age
Concentration
Correlation with age
Correlation 
coefficient (r) p-value
Correlation 
coefficient (r) p-value
Aβ 42 6.49 ± 1.25 pmol/L 0.0755 0.6432 6.32 ± 1.74 pmol/L 0.3802 0.0185*
ApoE 4776 ± 3238 ng/ml − 0.3833 0.0025** 4607 ± 2689 ng/ml 0.1369 0.3056
Clusterin 2534 ± 1397 ng/ml − 0.2536 0.0505 2516 ± 1336 ng/ml 0.0824 0.5386
Fibrinogen 49.59 ± 20.72 μg/ml 0.0570 0.6652 41.57 ± 21.72 μg/ml 0.2234 0.0918
Keratin 9 34.7 ± 47.6 pg/ml − 0.2316 0.0750 64.4 ± 88.0 pg/ml 0.1646 0.2168
SPARCL1 1126 ± 533 ng/ml 0.4619 0.0002*** 1204 ± 757 ng/ml 0.1711 0.1992
Tau 43.90 ± 13.78 ng/ml − 0.4082 0.0012** 43.10 ± 14.84 ng/ml 0.1062 0.4275
Table 2.  Blood plasma concentrations of putative AD biomarker targets as measured by immunoassay. 
Spearman correlation coefficients for protein concentration and patient age were determined using GraphPad 
Prism Version 5.02. A p-value ≤ 0.05 was considered statistically significant.
Molecule 1 Molecule 2
Healthy Cohort AD Cohort
Spearman 
correlation 
coefficient (r) p-value
Spearman 
correlation 
coefficient (r) p-value
Keratin 9 Aβ 42 0.1045 p = 0.5209 − 0.05246 p = 0.7478
Keratin 9 ApoE 0.3829 p = 0.0025** 0.6380 p < 0.0001****
Keratin 9 Clusterin 0.2707 p = 0.0364* 0.5276 p < 0.0001****
Keratin 9 Fibrinogen 0.1107 p = 0.3998 0.03512 p = 0.7899
Keratin 9 SPARCL1 − 0.3026 p = 0.0188* −0.3102 p = 0.0158*
Keratin 9 Tau 0.4338 p = 0.0005*** 0.6256 p < 0.0001****
Table 3.  Correlations between protein concentrations of Keratin 9 and other AD-associated molecules in 
blood plasma samples. Protein concentrations were determined using the appropriate ELISA of Luminex assay. 
Spearman correlation coefficients were determined for all protein pairings in healthy and AD patient cohorts 
using GraphPad Prism Version 5.02. A p-value ≤ 0.05 was considered statistically significant.
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VisANT analysis implies it may have further complex roles as it interacts with proteins that possess a wide range 
of functions (Table 4). The names and details of these proteins are listed in Table 4. Additionally, the interactome 
produced substantiates recent findings that Keratin 9 may have alternate expression sites to its well-characterised 
expression in palms and soles. For example, Keratin 9 has been shown to interact with IQCB139, which is localized 
in cilia of renal epithelial cells and, interestingly photoreceptor cells40. This adds weight to the recent discovery 
that Keratin 9 can be found in the proteome of tears8. One of the most important implications of this interactome 
is that it provides further validation of the presence of Keratin 9 in blood plasma10,16 as it can interact with five of 
the most abundant proteins in blood serum: Albumin, Apolipoprotein A-I and the heavy chain constant regions 
of Immunoglobins A, G and M41.
Further in silico Analysis: Expanding the Keratin 9 Interactome. Although this interactome pro-
vides a useful start point from which to understand the involvement of Keratin 9 in AD, it only details direct 
molecular interactions; expanding the interactome would highlight further biochemical pathways that may influ-
ence/be influenced by variations in Keratin 9 expression. With this in mind, we examined the additional interac-
tions of all 54 identified Keratin 9 interacting proteins. However, simply expanding every node resulted in high 
levels of complexity in the outputted data. We proceeded, therefore, to examine the interactions between Keratin 
9 and other molecules known to be involved in AD pathology directly rather than indirectly. VisANT was utilised 
to produce an interactome detailing the interactions of Keratin 9 with APP, Tau (MAPT) and ApoE, three mole-
cules with a longstanding association with AD (together, referred to as the AMA interactome). Molecules found 
to have two or more interacting partners within the derived network (i.e. they interact with at least two out of 
ApoE, APP, Keratin 9 and Tau) are included in the resultant interactome (Fig. 3). Correlations between expression 
levels of Keratin 9 and those of ApoE and Tau were earlier found to be disrupted in blood plasma samples from 
AD patients (Table 3). Whilst Keratin 9 has not yet been demonstrated to interact directly with APP, ApoE or Tau, 
Fig. 3 demonstrates that it is closely connected to all three molecules, requiring only one bridging molecule. The 
molecules found to interact with Keratin 9 and the AMA interactome are summarised in Table 4. In the case of 
ApoE Keratin 9 is linked via either VCAM1, ALB or UBC whilst for Tau it is linked via UBC and YWHAQ and for 
APP, it is linked via ALB, APOA1, COPS5, CUL3, CUL4B, GABARAPL2, GRB2, IGHM, MAP1LC3A, MDM2, 
NEDD8, PIK3R2, SHC1, TANK, TRAF3IP1, UBC and UCHL5. These molecular associations fail, however, to 
shed much more light on the problem since it is unlikely that Keratin 9 levels would affect APOE, MAPT or APP 
and vice versa through such a short pathway. Furthermore, many of the linking molecules, such as UBC, are ubiq-
uitously expressed and interact with a broad range of proteins so any effect manifesting through these molecules 
would not explain the specificity of AD symptoms. It is therefore necessary to expand the interactome network: a 
series of several, more specific interactions that link these proteins is potentially the key to solving the problem as 
opposed to searching for the shortest connection paths. One way to solve this problem, whilst avoiding generating 
too much complexity in the interactome, is to place Keratin 9 in the context of pathways that are already thought 
to play a role in AD.
In previous work we have used Reactome (http://www.reactome.org/)25,42 to identify pathways in which AD 
biomarkers may be participating25. Initially, the same approach was implemented here whereby Keratin 9 and all 
54 of its interacting molecules that were identified through VisANT were inputted into Reactome. However 10 
out of these 55 molecules, including Keratin 9, were not found in the Reactome database, and as a consequence 
this method was deemed inappropriate for determining the pathways associated with Keratin 9. Instead, the func-
tions of each of the Keratin 9 interacting proteins were evaluated using the UniProtKB database, which displays 
Figure 2. A basic Keratin 9 interactome determined using VisANT software. The interactome comprises 
the 54 proteins demonstrated to interact directly with Keratin 9 with the lines linking each node colour coded 
according to method used to establish the interaction. Further information on the nodes and interactions can be 
found in Table 4.
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KRT9 interacting partner
Experimental Evidence of 
Interaction Reference
Direct Link to AMA 
Interactome
APP APOE MAPT
ADAM metallopeptidase domain 3B (ADAM3B) Two-hybrid Test 72 — — —
Adrenoceptor beta 2, surface (ADRB2) Affinity Capture-MS 73 — — —
Albumin (ALB) Affinity Capture-MS; Anti-Bait Coimmunoprecipitation 41 ✓ ✓ —
Adaptor-related protein complex 2, mu 1 subunit (AP2M1) Affinity Capture-MS 67 — — —
Adenomatous polyposis coli (APC) Surface Plasmon Resonance 74 — — —
Apolipoprotein A-I (APOA1) Affinity Capture-MS; Anti-Bait Coimmunoprecipitation 41 ✓ — —
Cullin-associated and neddylation-dissociated 1 (CAND1) Affinity Capture-MS 66 — — —
Cbl proto-oncogene, E3 ubiquitin protein ligase (CBL) Affinity Capture-MS 67 — — —
Cadherin 1, type 1, E-cadherin (epithelial) (CDH1) Affinity Capture-MS; Surface Plasmon Resonance 74 — — —
Cystic fibrosis transmembrane conductance regulator (CFTR) Anti-Bait Coimmunoprecipitation 75 — — —
COP9 signalosome subunit 5 (COPS5) Affinity Capture-MS 66 ✓ — —
COP9 signalosome subunit 6 (COPS6) Affinity Capture-MS 66 — — —
V-crk avian sarcoma virus CT10 oncogene homolog (CRK) Affinity Capture-MS 67 — — —
Cullin 1 (CUL1) Affinity Capture-MS 66 — — —
Cullin 2 (CUL2) Affinity Capture-MS 66 — — —
Cullin 3 (CUL3) Affinity Capture-MS 66 ✓ — —
Cullin 4A (CUL4A) Affinity Capture-MS 66 — — —
Cullin 4B (CUL4B) Affinity Capture-MS 66 ✓ — —
Cullin 5 (CUL5) Affinity Capture-MS 66 — — —
DCN1, defective in cullin neddylation 1, domain containing 1 (DCUN1D) Affinity Capture-MS 66 — — —
E2F transcription factor 3 (E2F3) Pull Down 76 — — —
Eukaryotic translation initiation factor 4A3 (EIF4A3) Affinity Capture-MS 77 — — —
Epidermal growth factor receptor pathway substrate 15 (EPS15) Affinity Capture-MS; Anti-Tag Coimmunoprecipitation 67 — — —
Fibronectin 1 (FN1) Affinity Capture-MS 78 — — —
GABA(A) receptor-associated protein (GABARAP) Anti-Tag Coimmunoprecipitation 79 — — —
GABA(A) receptor-associated protein like 1 (GABARAPL1) Anti-Tag Coimmunoprecipitation 79 — — —
GABA(A) receptor-associated protein like 2 (GABARAPL2) Anti-Tag Coimmunoprecipitation 79 ✓ — —
Growth factor receptor-bound protein 2 (GRB2) Affinity Capture-MS 67 ✓ — —
Immunoglobulin heavy constant alpha 1 (IGHA1) Anti-Bait Coimmunoprecipitation 41 — — —
Immunoglobulin heavy constant gamma 1 (IGHG1) Anti-Bait Coimmunoprecipitation 41 — — —
Immunoglobulin heavy constant mu (IGHM) Anti-Bait Coimmunoprecipitation 41 ✓ — —
Inositol polyphosphate phosphatase-like 1 (INPPL1) Affinity Capture-MS 67 — — —
IQ motif containing B1 (IQCB1) Affinity Capture-MS 39 — — —
Integrin, alpha 4 (ITGA4) Affinity Capture-MS 80 — — —
Keratin 1 (KRT1) Co-Fractionation 81 — — —
Leucine-rich repeat containing G protein-coupled receptor 4 (LGR4) Affinity Capture-MS 82 — — —
Mago-nashi homolog, proliferation-associated (MAGOH) Affinity Capture-MS 77 — — —
Microtubule-associated protein 1 light chain 3 alpha (MAP1LC3A) Anti-Tag Coimmunoprecipitation 79 ✓ — —
Microtubule-associated protein 1 light chain 3 beta (MAP1LC3B) Anti-Tag Coimmunoprecipitation 79 — — —
MDM2 proto-oncogene, E3 ubiquitin protein ligase (MDM2) Affinity Capture-MS 69 ✓ — —
Neural precursor cell expressed, developmentally down-regulated 8 (NEDD8) Affinity Capture-MS 66 ✓ — —
Phosphoinositide-3-kinase, regulatory subunit 2 (beta) (PIK3R2) Affinity Capture-MS 67 ✓ — —
POU class 5 homeobox 1 (POU5F1) Affinity Capture-MS 83 — — —
Protein phosphatase 2, regulatory subunit B, beta (PPP2R2B) Pull Down; Anti-Tag Coimmunopreciptation 84 — — —
SH3-domain GRB2-like 3 (SH3GL3) Two Hybrid Test 72 — — —
Src homology 2 domain containing transforming protein 1 (SHC1) Affinity Capture-MS 67 ✓ — —
TRAF family member-associated NFKB activator (TANK) Functional Linkage Network; Anti-Tag Coimmunoprecipitation 85 ✓ — —
TNF receptor-associated factor 3 interacting protein 1 (TRAF3IP1)
Anti-Bait 
Coimmunoprecipitation; Affinity 
Capture-MS
86 ✓ — —
Ubiquitin associated and SH3 domain containing B (UBASH3B) Affinity Capture-MS 67 — — —
Continued
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the complete Gene Ontology annotation as well as a full list of Reactome entries for each protein. Additionally, 
since VisANT only displays proteins that share physical interactions, we searched the literature for evidence of 
transcriptional regulation of Keratin 9 to establish whether Keratin 9 regulators play a role in AD. As a result of 
this, several pathways linked to these interacting proteins and regulatory proteins were highlighted, including wnt 
signalling and the ubiquitin proteasome system which have already been linked to AD43–45.
Wnt Signalling in AD. The canonical wnt signalling pathway regulates the expression of a wide range 
of genes throughout the body and has been strongly implicated in AD43,44. The cascade is initiated when wnt 
ligands complex with LRP5/6 and Frizzled (Fz) receptors. Fz then activates Dishevelled protein, which forms 
a complex with GSK3β , adenomatous polyposis coli (APC), Axin and beta-catenin resulting in inactivation 
of GSK3β and stabilization of beta-catenin. Beta catenin can then bind to T cell receptor (Tcf)/Lymphoid 
enhancer-binding factor (LEF) transcription factors by displacement of the repressor protein, Groucho leading 
to activation or repression of target genes. In the absence of wnt, or in the presence of a wnt antagonist, GSK3β 
remains active, facilitating phosphorylation of beta-catenin, which is targeted to the ubiquitin-proteasome 
degradation pathway44. This prevents beta-catenin from entering the nucleus and interacting with transcrip-
tion factors. It is thought that downregulation of components of this cascade can result in many of the key 
changes that occur in the AD brain: repression of wnt signalling has so far been linked to the processing of 
APP, Aβ peptide neurotoxicity and tau phosphorylation43. For example beta secretase (BACE1), the APP cleav-
ing enzyme, is suppressed following wnt activation via beta-catenin binding to TCF4, a BACE1 promoter46. 
Therefore, downregulation of the wnt pathway can result in increased cleavage of APP and therefore increased 
Aβ levels.
VisANT analysis suggests that Keratin 9 may be linked to this cascade via interactions with APC and 
Cadherin 1 (CDH1), which interacts with β -catenin in adherens junctions. It is unlikely however, that Keratin 
9 could affect this pathway through binding to CDH1 or APC as there is no evidence of Keratin 9 acting as a 
signalling molecule. It is more likely that Keratin 9 levels could be influenced by this pathway as it has been 
suggested that wnt signalling may be involved in keratinocyte development. Dickkopf 1 (DKK1), an antagonist 
of the wnt pathway, has been shown to induce the expression of Keratin 9, resulting in a thicker epidermis47. 
Furthermore, increased expression of DKK1 has been seen in brain tissue of AD patients and this has been 
causally linked to the neurodegeneration associated with the disease48. It is thought that expression of Aβ 
induces expression of DKK1 in a P53 dependent manner and conversely, repressing DKK1 reduces Aβ toxic-
ity49. Increased expression of DKK1 could therefore not only help explain the characteristic amyloid beta tox-
icity, but also the presence of Keratin 9 in the CSF of AD patients. Although, to our knowledge, this is the first 
time a link has been proposed between DKK1 and Keratin 9 in non-epidermal tissue, both DKK1 and Keratin 
9 have separately been shown to have diagnostic potential for hepatocellular carcinoma due to their dysregu-
lation in blood serum10,50. This suggests that, in certain disease conditions, DKK1 could induce the expression 
of Keratin 9 in non-epidermal tissue.
Interestingly, our results also show a correlation between changes in Keratin 9 and Clusterin levels in AD 
(Table 3). This could be explained by previous research by Killick and colleagues49, which suggests linkages 
between Clusterin, DKK1 and Aβ . They found that knockdown of Clusterin expression results in reduced Aβ 
toxicity and DKK1 expression, suggesting that Aβ induced DKK1 expression is dependent on Clusterin, as well 
as P53. They also highlighted a potential mechanism, thought to be the amyloid cascade, whereby Clusterin 
mediates neurotoxicity in an Aβ induced clusterin/P53/DKK1/wnt-PCP-JNK pathway. Since our immunoassay 
detection did not include DKK1 or P53, we can only speculate that these may be linked to Clusterin and Keratin 9 
based on previous research. It would therefore be of interest to include DKK1 and P53 in our biomarker panel in 
future in order to establish for ourselves whether these correlate with Clusterin, Aβ or Keratin 9.
Keratin 9 and Blood Brain Barrier Dysregulation in AD. The presence of Keratin 9 in CSF has previ-
ously been demonstrated using various mass spectrometry techniques12,15 and 2D electrophoresis13, but these 
techniques gave no indication of the concentration at which it existed. To our knowledge, the first immunoassay 
validation of the presence of Keratin 9 in CSF was obtained during our previous study which demonstrated the 
presence of Keratin 9 in the CSF of AD patients but not in healthy individuals16. Keratin 9 has also been identified 
in the proteome of blood plasma multiple times41,51–62. Although sample contamination cannot be ruled out, and 
we can only speculate on why Keratin 9 is present in blood, the sheer number of studies documenting this result 
adds plausibility to our finding of Keratin 9 in blood plasma in both healthy and AD patients. Furthermore, our 
KRT9 interacting partner
Experimental Evidence of 
Interaction Reference
Direct Link to AMA 
Interactome
APP APOE MAPT
Ubiquitin C (UBC) Affinity Capture-MS 68 ✓ ✓ ✓
Ubiquitin carboxyl-terminal hydrolase L5 (UCHL5) Affinity Capture-MS 87 ✓ — —
PAN2 poly (A) specific ribonuclease subunit (USP52) Affinity Capture-MS 88 — — —
Vascular cell adhesion molecule 1 (VCAM1) Cross-linking Studies; Affinity Capture-MS 78,80 — ✓ —
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, 
theta (YWHAQ)
In vivo; Coimmunoprecipitation; 
Affinity Capture-MS 89 — — ✓
Table 4.  Components of the Keratin 9 interactome determined using VisANT software. The means of 
determining their interaction with Keratin 9 and their links to the AMA Interactome are displayed.
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finding that Keratin 9 was present in the CSF of AD individuals but not in healthy individuals16, could suggest 
that there are differences in the blood brain barrier (BBB), enabling Keratin 9 to pass from the blood into CSF in 
AD individuals.
Dysfunction of the BBB has already been strongly implicated in AD. The integrity of the BBB is compro-
mised in AD due to down-regulation of Claudin proteins, resulting in destabilisation of tight junctions between 
endothelial cells63. Evidence also suggests that p-glycoprotein, an Aβ transporter at the BBB, is down-regulated 
in AD, resulting in compromised Aβ clearance and accumulation of Aβ in the brain64. Interestingly, expression 
of p-glycoprotein and maintenance of tight junctions in the BBB are known to be regulated by the wnt signalling 
pathway63,65. Increased expression of DKK1, as mentioned previously, inhibits this pathway and therefore con-
tributes to increased BBB permeability, decreased p-glycoprotein expression and Aβ accumulation. Increased 
permeability of the BBB could therefore enable Keratin 9, which is up-regulated by DKK147, to pass from blood 
to CSF in AD patients.
Keratin 9 and the Ubiquitin Proteasome System in AD. The interactome produced using VisANT 
and subsequent analysis revealed that at least 12 of the Keratin 9 interacting partners: CAND1, CBL, CUL1, 
CUL2, CUL3, CUL4A, CUL4B, CUL5, DCUN1D, MDM2, NEDD8 and UBC, are components of the Ubiquitin 
Proteasome System (UPS)66–69. This suggests that Keratin 9 may be ubiquitinated and targeted for degradation by 
the proteasome. However, the abnormal presence of Keratin 9 in CSF and the elevated levels of Keratin 9 in blood 
of AD patients indicate a failure in this system, which prevents Keratin 9 degradation. Dysregulation of the UPS 
has previously been linked to AD as a significant decrease in proteasome activity has been observed in various 
regions of the AD brain and this is thought to result in the aggregation of Aβ into plaques45. This may also explain 
the build-up of Keratin 9 and therefore Keratin 9 may be a useful biomarker to detect the UPS dysregulation 
associated with AD.
Keratin 9: More than just a structural molecule. In addition to functioning as scaffolding proteins 
within cellular cytoskeletons, some keratins are known to be involved in cell signalling, communicating with 
extracellular matrix (ECM) components and other cells through desmosomes and hemidesmosomes70,71. 
Although Keratin 9 has not yet been implicated in any signalling pathways, VisANT analysis reveals interactions 
with several cytoskeletal and ECM components, implying a potential signalling role. Specifically, Keratin 9 inter-
acts with CDH1 and ITGA4, which are involved in cell-cell junctions and cell-matrix interactions, and FN1, a 
component of the ECM. Keratin 9 also interacts directly with other cytoskeletal components, including KRT1 and 
indirectly with microtubules through interactions with MAP1LC3A and MAP1LC3B. There is a wide range of 
other proteins with which Keratin 9 also interacts (Table 4) for which the implications of the interactions are cur-
rently unclear. As these proteins have a variety of functions it could be speculated that the interactions may have 
unforeseen consequences for other downstream pathways. If this were to be proven and if the affected pathways 
influence AD it would mean that dysregulation of Keratin 9 expression, which currently appears to be a conse-
quence of AD, may have consequences of its own that may contribute to AD onset and progression.
Figure 3. The Interactome of Keratin 9, Apolipoprotein E (APOE), Tau (MAPT) and Amyloid Precursor 
Protein (APP) (nodes shown in red). VisANT software was used to identify all interacting molecules. 
Interacting molecules are identified as green (interacting with 2 proteins), yellow (interacting with 3 
proteins), or blue (interacting with 4 proteins). Proteins with only a single interaction were excluded from the 
Interactome. Only the nodes with direct links to Keratin 9 have been labelled.
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Conclusion
Rapidly emerging evidence suggests that Alzheimer’s disease is multifactorial and therefore, finding a single 
marker for the disease is not the key to early diagnosis. With this in mind, we do not present Keratin 9 as a 
stand-alone biomarker for the disease but rather, a useful component of a biomarker panel. The use of Keratin 
9 as a biomarker seems controversial and counterintuitive considering that is was until recently believed to be 
solely expressed in terminally differentiated layers of the epidermis. However, biochemical analysis of expression 
patterns and in silico mapping of keratin 9 interactions has proved to be useful in understanding potential mecha-
nisms that may explain the involvement of keratin 9 in the disease. These pathways, alongside other proposed AD 
risk factors and their likely role in AD pathology are summarized in Fig. 4. We can speculate from our research 
that the abnormal expression of keratin 9 in AD is likely the consequence of dysregulated signalling pathways, 
notably wnt signalling pathways and potentially the UPS, in addition to a break-down in the BBB. Based on this 
information, we suggest that P53 and DKK1 should also be considered as potential biomarkers in addition to the 
panel of markers we identified previously. Furthermore, the interactome of keratin 9 also suggests that its abnor-
mal expression may have other downstream consequences resulting from its interactions with a broad range of 
other molecules, so this may be a potential area for future research.
Figure 4. Keratin 9 in Alzheimer’s disease pathology. The diagram illustrates how Keratin 9 may interact with 
some of the major known factors in Alzheimer’s disease including those pathways which implicate ApoE, APP, 
Clusterin and Tau. Dotted lines indicate unknown mechanisms.
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